Literature DB >> 994627

[Results of veno-venous shunt with arterialization of the liver (author's transl)].

U Matzander.   

Abstract

Since 1968, arterialization of the liver with a portacaval shunt has been carried out in 82 patients for the treatment of portal hypertension caused by cirrhosis. Lethality in the first 4 weeks after operation was 19%. In 35 patients it is now over 5 years since the operation, 5 years survival being 46%. The general condition of these patients is remarkably good. The liver's detoxifying function has been preserved. Encephalopathy is rare. In cases of existing portacaval shunt arterialization can still be performed by way of the V. umbilicalis. The detoxifying function will improve after this.

Entities:  

Mesh:

Year:  1976        PMID: 994627     DOI: 10.1007/bf01267361

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  2 in total

1.  [Method and technic of pressure-adapted liver arterialization with portacaval anastomosis].

Authors:  U Matzander
Journal:  Chirurg       Date:  1974-05       Impact factor: 0.955

2.  [Problems in the arterialization of the intrahepatic portal vein circulation followingporto-caval anastomosis].

Authors:  U Matzander
Journal:  Langenbecks Arch Chir       Date:  1968
  2 in total
  4 in total

1.  Flow- and pressure-adapted portal arterialization in dogs.

Authors:  H Asakawa; S Kasai; M Mito
Journal:  Jpn J Surg       Date:  1985-07

2.  Hepatopedal flow restoration in patients intolerant of total portal diversion.

Authors:  J G Chandler; R E Fechner
Journal:  Ann Surg       Date:  1983-05       Impact factor: 12.969

3.  [Portal hypertension].

Authors:  H Denck
Journal:  Langenbecks Arch Chir       Date:  1984

4.  Portal vein arterialization promotes liver regeneration after extended partial hepatectomy in a rat model.

Authors:  Jian Li; Chaonong Cai; Hui Guo; Xiaodong Guan; Lukun Yang; Yuechan Li; Yanhua Zhu; Peiping Li; Xialei Liu; Baimeng Zhang
Journal:  J Biomed Res       Date:  2014-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.